Midatech Pharma Plc EV/EBITDA
¿Qué es el EV/EBITDA de Midatech Pharma Plc?
El EV/EBITDA de Midatech Pharma Plc es 0.40
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en LSE en comparadas con Midatech Pharma Plc
¿Qué hace Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Empresas con ev/ebitda similar a Midatech Pharma Plc
- Northern Bitcoin AG tiene EV/EBITDA de 0.39
- Jilin Province Huinan Changlong Bio-pharmacy tiene EV/EBITDA de 0.39
- Cassowary Capital tiene EV/EBITDA de 0.39
- SciPlay tiene EV/EBITDA de 0.40
- Mmtec tiene EV/EBITDA de 0.40
- Meat-Tech 3D Ltd tiene EV/EBITDA de 0.40
- Midatech Pharma Plc tiene EV/EBITDA de 0.40
- Teras Resources tiene EV/EBITDA de 0.40
- WestStar Industrial tiene EV/EBITDA de 0.40
- Gulfport tiene EV/EBITDA de 0.40
- SDX Plc tiene EV/EBITDA de 0.40
- Harpoon Therapeutics tiene EV/EBITDA de 0.41
- Litho Formas, S.A tiene EV/EBITDA de 0.41